A surprising observation in the lab has revealed a remarkable ability in Stentor coeruleus, a single-celled organism about one millimeter long. Sometimes nicknamed the “platypus” of microorganisms for its trumpet-like shape, this tiny creature appears to have a distinct preference for corners.
A new blood test combined with a standardized questionnaire and artificial intelligence may transform the way leprosy is diagnosed in Brazil. The method showed potential for identifying the disease in its initial stages, when symptoms are subtle and traditional laboratory tests often fail.
New research shows that bacteria incorporate polyfluoroalkyl carboxylates—a type of Per- and Polyfluoroalkyl Substances (PFASs)—into the molecules that make up their cell membranes.
A new study has revealed two novel species of Neohelicomyces fungi: Neohelicomyces coffeae and Neohelicomyces puerensis. While studying the fungi that live on Coffea arabica, researchers spotted these unique organisms growing on dead coffee branches.
Tuberculosis rates for Inuit living in Nunavik, the Inuit lands in northern Quebec, are 1,000 times greater than among non-foreign-born Quebeckers, and underresourcing of local health care adds to hardship from the disease, found new research.
Researchers have created the first mouse model in which chronic viral infection progresses to liver cancer, closely mirroring what happens in people with hepatitis C.
A surprising observation in the lab has revealed a remarkable ability in Stentor coeruleus, a single-celled organism about one millimeter long. Sometimes nicknamed the “platypus” of microorganisms for its trumpet-like shape, this tiny creature appears to have a distinct preference for corners.
New research shows that bacteria incorporate polyfluoroalkyl carboxylates—a type of Per- and Polyfluoroalkyl Substances (PFASs)—into the molecules that make up their cell membranes.
A new study has revealed two novel species of Neohelicomyces fungi: Neohelicomyces coffeae and Neohelicomyces puerensis. While studying the fungi that live on Coffea arabica, researchers spotted these unique organisms growing on dead coffee branches.
The Vanderbilt Center for Antibody Therapeutics has signed an option agreement with Saravir Biopharma Inc. for the company to develop human monoclonal antibodies isolated in the laboratory of James Crowe Jr., MD, for the treatment and prevention of measles.
UK-BASED cleanroom engineering company Total Clean Air (TCA), a UKAS ISO 17025-accredited cleanroom constructor, has been appointed European partner for US-based decontamination technology firm TOMI®Environmental Solutions.
EnteroBiotix announced that the investigator-initiated Phase 2a MAST trial has completed its enrolment of 50 adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT) for defined haematological malignancies.
A new blood test combined with a standardized questionnaire and artificial intelligence may transform the way leprosy is diagnosed in Brazil. The method showed potential for identifying the disease in its initial stages, when symptoms are subtle and traditional laboratory tests often fail.
Researchers have developed a microscopic DNA needle that delivers molecules directly into cells and helps keep them active. It may solve a major problem in modern medicine: many therapies are trapped inside cells and lose their effect.
Research shows the vaccine — in combination with drug therapy — accelerated a relapse-free TB cure in mice, improved activity of a drug-resistant TB regimen and stimulated immune responses in nonhuman primates.
The Global Virus Network (GVN) announced the launch of its expanded Global Guardians for Pandemic Preparedness initiative, with applications now open for high school students across the state of Florida.
Two research groups are bringing together two complementary scientific approaches to discover new antifungal agents – targeting Fusarium, but also those derived from Fusarium.
A new inquiry by the UK Parliament’s Science and Technology Committee investigates why the NHS adoption of the UK’s cutting-edge life sciences innovations often fails - and what could be done to fix it. Members of AMI could be just the people to provide answers.